UK finalises US pharma deal granting tariff-free access for British medicines - Reuters

<a href="https://news.google.com/rss/articles/CBMixwFBVV95cUxQUTA4djBMVHlQMnJDLXMzbkx6OVQ3dzRyekE2OTNUUmVyQWFBMk5YZDJablJHZGI4OGZrM0poeV9CSkp4bDVWNGFxcGwxSml6SGpRMFV1U1d0bUx4Uy1oaXdFVVpDa2duemM4UmgzQ0FZdkV2ZnhQdjFPOE0yUllmemU5LURBRVkxS1VoenZOSjlvc1ltdkZYZklfdmx0LVVHb2l4WHAwUHZ1UHg5THBkTzk0enVGcTc0U0Nvbm9SN2NBcVZ4alMw?oc=5" target="_blank">UK finalises US pharma deal granting tariff-free access for British medicines</a>&nbsp;&nbsp;<font color="#6f6f6f">Reuters</font>

Britain has finalised a U.S.-UK pharmaceutical trade deal, setting out tariff-free access for UK-made medicines to the United States for at least three years.

The U.K. has officially secured zero tariffs on drug exports to the U.S., aiming to reattract biopharma investment by increasing NHS spending on new medicines by 25%.

The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, marking a significant milestone in post-Brexit trade strategy and transatlantic economic alignment.

Britain has agreed the full text of a U.S.-UK pharmaceutical partnership, setting out terms under which British-made medicines would enter the United States tariff-free.

Britain has agreed the full text of a U.S.-UK pharmaceutical partnership, setting out terms under which British-made medicines would enter the United States tariff-free.